Research programme: autoimmune disorder therapeutics

Drug Profile

Research programme: autoimmune disorder therapeutics

Alternative Names: AI-001

Latest Information Update: 31 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of British Columbia
  • Developer BirchBioMed
  • Class Cell therapies; Hydroxyquinolines; Small molecules
  • Mechanism of Action Connective tissue growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alopecia; Psoriasis; Type 1 diabetes mellitus

Most Recent Events

  • 25 Aug 2016 BirchBioMed in-licenses kynurenic acid and AI 001 from University of British Columbia before June 2016
  • 28 Aug 2015 Preclinical trials in Alopecia in Canada (unspecified route)
  • 28 Aug 2015 Preclinical trials in Psoriasis in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top